Table 1 Patients groups characteristics (N = 294)
| Characteristics | n | 5 year survival (%) | p overall (log rank test) |
|---|---|---|---|
| Treatment period | |||
| 2004 | 152 | 80.3 | p = .42 |
| 2005 | 97 | 79.4 | |
| 2006 | 21 | 90.0 | |
| 2007 | 19 | 68.4 | |
| Tumor stage | |||
| I | 67 | 83.2 |
P < .001 pairwise comparisons 1–3, **, 2–3 ** |
| II | 201 | 81.0 | |
| III | 26 | 50.0 | |
| Lymph node involvement | |||
| Not involved | 179 | 82.0 | p = .51 |
| Involved | 115 | 76.8 | |
| ER and HER2 receptor status | |||
| ER-HER2- | 85 | 66.5 |
p = .002 pairwise comparisons 1–3 *, 3–4 * 1–4 ** |
| ER-HER2+ | 17 | 87.5 | |
| ER + HER2- | 143 | 79.8 | |
| ER + HER2+ | 49 | 93.9 | |
| Menopausal status | |||
| Pre/perimenopausal | 94 | 85.3 | p < .05 |
| Postmenopausal | 200 | 75.5 | |
| Delayed number of cycles | |||
| ≤ 2 delayed cycles | 187 | 86.3 | p < .001 |
| > 2 delayed cycles | 107 | 65.4 | |
| Delayed number of days at any cycle | |||
| ≤ 7 days | 217 | 81.1 | p = .093 |
| ˃7 days | 77 | 71.8 | |
| Dose reduction | |||
| ≤ 15% | 225 | 89.7 | p < .001 |
| ˃ 15% | 69 | 65.4 | |
| Anthracycline delay/reduction groups | |||
| No anthracyclines reduction or delays | 179 | 86.4 |
p < .001 pairwise comparisons 1–2, 1–4 ** 2–3, 3–4 * 1–3, 2–4 ns |
| Anthracycline reduction only | 38 | 57.6 | |
| Anthracycline delays only | 46 | 79.5 | |
| Both anthracycline reduction and delays | 31 | 60.2 | |
